Bezafibrate
- Generic Name
- Bezafibrate
- Brand Names
- Bezalip
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20ClNO4
- CAS Number
- 41859-67-0
- Unique Ingredient Identifier
- Y9449Q51XH
- Background
Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.
- Indication
For the treatment of primary hyperlipidaemia types IIa, IIb, III, IV and V (Fredrickson classification) corresponding to groups I, II and III of the European Atherosclerosis Society guidelines - when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. Also for the treatment of secondary ...
- Associated Conditions
- Fredrickson classification type IV Hyperlipidemia, Fredrickson classification type V Hyperlipidemia, Primary Hypercholesterolemia, Type IIb hyperlipoproteinaemia
- Associated Therapies
- -
The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)
- Conditions
- Interventions
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2011-08-10
- Target Recruit Count
- 10
- Registration Number
- NCT01165060
- Locations
- 🇳🇱
Academisch Medisch Centrum, Amsterdam, NH, Netherlands
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects
- Conditions
- Interventions
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2012-05-30
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 12
- Registration Number
- NCT00983788
- Locations
- 🇩🇰
Neuromusculare Research Unit, Rigshospitalet, Copenhagen, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.